Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study

Fig. 2

Reactions after boost COVID-19 vaccination in a homologous or heterologous regimen. Solicited and unsolicited reactions 14 to 19 days after boost COVID-19 vaccination in participants with homologous (mRNA/mRNA or ChAdOx1/ChAdOx1) or heterologous (ChAdOx1/mRNA) prime-boost vaccination regimen with consequences in hierarchical order, as multiple choice was possible. The consequence perceived as most serious is reported (from no consequence to medication intake, sick leave, outpatient (practice) consultation, clinic (ambulant) consultation, and hospitalisation). Local reactions are a composite of pain, erythema, or swelling, mobility restriction, and abscess. Systemic reactions are a composite of the reactions from headache to coagulation disorder. ChAdOx1: ChAdOx1 (AstraZeneca). mRNA: BNT162b2 (BioNTech/Pfizer) or mRNA-1273 (Moderna)

Back to article page